ACC's awards programs support the development of the next generation of clinicians and scientists, advance research and honor those who have made a difference in cardiology. Transforming ...

Congress has passed an appropriations package funding Labor, Health and Human Services, Education and Related Agencies for the remainder of fiscal year (FY) 2026. The legislation includes several high ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

Late-breaking clinical trials presented at ACC.26 focusing on coronary interventions included several looking at intravascular guidance in complex, high-risk procedures (IVUS-CHIP), bifurcation ...

In this week’s View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new ...

In this week’s View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on ...

Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

Finerenone is a nonsteroidal MRA with selective receptor binding, distinct co-regulator interactions and balanced heart-kidney distribution – properties that together produce a more targeted ...

In his Editor's Page Harlan M. Krumholz, MD, SM, MACC, discusses what he calls the "most important unsolved problem" with treating dyslipidemia. "Too many patients who could benefit greatly are not ...

Erectile dysfunction (ED) is a risk marker of cardiovascular disease (CVD) and should be considered a risk-enhancing factor when considering the intensity of risk-factor reduction. Patients with ED ...

CMS has proposed ending Coverage with Evidence Development (CED) requirements for patients with symptomatic severe aortic stenosis (AS) while expanding CED to include patients with asymptomatic severe ...